JP2001516732A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001516732A5 JP2001516732A5 JP2000511728A JP2000511728A JP2001516732A5 JP 2001516732 A5 JP2001516732 A5 JP 2001516732A5 JP 2000511728 A JP2000511728 A JP 2000511728A JP 2000511728 A JP2000511728 A JP 2000511728A JP 2001516732 A5 JP2001516732 A5 JP 2001516732A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- straight
- group
- chain
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 description 124
- 125000000217 alkyl group Chemical group 0.000 description 67
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 58
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 47
- 150000001875 compounds Chemical class 0.000 description 42
- 239000001257 hydrogen Substances 0.000 description 42
- 229910052739 hydrogen Inorganic materials 0.000 description 42
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 37
- -1 nitro, carboxyl Chemical group 0.000 description 33
- 229910052736 halogen Inorganic materials 0.000 description 32
- 150000002431 hydrogen Chemical class 0.000 description 32
- 125000003545 alkoxy group Chemical group 0.000 description 31
- 125000002947 alkylene group Chemical group 0.000 description 30
- 150000002367 halogens Chemical group 0.000 description 30
- 229910052801 chlorine Inorganic materials 0.000 description 28
- 239000000460 chlorine Substances 0.000 description 28
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 28
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 27
- 229910052731 fluorine Inorganic materials 0.000 description 27
- 239000011737 fluorine Substances 0.000 description 27
- 125000001424 substituent group Chemical group 0.000 description 27
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 22
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 21
- 229910052794 bromium Inorganic materials 0.000 description 21
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 19
- 125000002252 acyl group Chemical group 0.000 description 17
- 229910052717 sulfur Inorganic materials 0.000 description 17
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 12
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 11
- 125000001153 fluoro group Chemical group F* 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 125000004434 sulfur atom Chemical group 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 229910052727 yttrium Inorganic materials 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 125000003831 tetrazolyl group Chemical group 0.000 description 7
- 150000001540 azides Chemical class 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000003003 spiro group Chemical group 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 0 COCc(c(*)c(*)c(*)c1)c1N Chemical compound COCc(c(*)c(*)c(*)c1)c1N 0.000 description 4
- 238000003747 Grignard reaction Methods 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000005055 alkyl alkoxy group Chemical group 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229910052752 metalloid Inorganic materials 0.000 description 4
- 150000002738 metalloids Chemical class 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 125000005353 silylalkyl group Chemical group 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000005254 oxyacyl group Chemical group 0.000 description 3
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 238000006584 Barton reaction Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000002366 halogen compounds Chemical class 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 125000004544 purin-8-yl group Chemical group N1=CN=C2N=C(NC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000006884 silylation reaction Methods 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 150000003608 titanium Chemical class 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19741050 | 1997-09-18 | ||
| DE19741050.2 | 1997-09-18 | ||
| DE19832159.7 | 1998-07-17 | ||
| DE19832159A DE19832159A1 (de) | 1997-09-18 | 1998-07-17 | Substituierte Tetrahydro-naphthaline |
| PCT/EP1998/005874 WO1999014174A1 (de) | 1997-09-18 | 1998-09-16 | Substituierte tetrahydro-naphtaline und analoge verbindungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001516732A JP2001516732A (ja) | 2001-10-02 |
| JP2001516732A5 true JP2001516732A5 (enExample) | 2006-01-05 |
Family
ID=26040079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000511728A Pending JP2001516732A (ja) | 1997-09-18 | 1998-09-16 | 置換テトラヒドロナフタリンおよび類似化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6586613B1 (enExample) |
| EP (1) | EP1017659B1 (enExample) |
| JP (1) | JP2001516732A (enExample) |
| AT (1) | ATE294152T1 (enExample) |
| AU (1) | AU9744298A (enExample) |
| ES (1) | ES2242302T3 (enExample) |
| MA (1) | MA24643A1 (enExample) |
| PT (1) | PT1017659E (enExample) |
| WO (1) | WO1999014174A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| ATE242007T1 (de) | 1998-12-23 | 2003-06-15 | Searle Llc | Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen |
| DE19935966A1 (de) * | 1999-07-30 | 2001-02-01 | Bayer Ag | Verfahren zur Reduktion von Ketoalkoholen |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| WO2003000235A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| NZ529490A (en) | 2001-06-22 | 2005-08-26 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drug |
| DE10148436A1 (de) * | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| FR2832919B1 (fr) | 2001-12-04 | 2004-02-20 | Imv Technologies | Seringue d'injection du contenu d'une paillette pour l'insemination artificielle d'un animal ou le transfert embryonnaire |
| WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| BR0215240A (pt) | 2001-12-19 | 2004-10-26 | Atherogenics Inc | Derivados de calcona e seu uso no tratamento de doenças |
| AU2003207431A1 (en) | 2002-01-17 | 2003-09-02 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepines. |
| ES2305434T3 (es) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| CA2508840A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| ATE534381T1 (de) | 2003-03-17 | 2011-12-15 | Japan Tobacco Inc | Pharmazeutische cetp-inhibitor-zusammensetzungen |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| CA2532931A1 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| EP2319509A1 (en) | 2003-09-26 | 2011-05-11 | Japan Tobacco, Inc. | Method of Inhibiting remnant lipoprotein production |
| WO2006063828A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente |
| US8617604B2 (en) | 2005-02-03 | 2013-12-31 | Bend Research, Inc. | Pharmaceutical compositions with enhanced performance |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| AU2006304836A1 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| DE102006012548A1 (de) | 2006-03-18 | 2007-09-20 | Bayer Healthcare Ag | Substituierte Chromanol-Derivate und ihre Verwendung |
| ATE520696T1 (de) * | 2008-03-05 | 2011-09-15 | Boehringer Ingelheim Int | Tricyclische pyridinderivate, solche verbindungen enthaltende medikamente, ihre verwendung und verfahren zu ihrer herstellung |
| US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| US9187450B2 (en) | 2010-07-09 | 2015-11-17 | Daiichi Sankyo Company, Limited | Substituted pyridine compound |
| WO2016037534A1 (en) | 2014-09-09 | 2016-03-17 | Boehringer Ingelheim International Trading (Shanghai) Co. Ltd. | Novel process for preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169857A (en) | 1988-01-20 | 1992-12-08 | Bayer Aktiengesellschaft | 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis |
| US5446207A (en) * | 1993-09-01 | 1995-08-29 | Harbor Branch Oceanographic Institution, Inc. | Anti-dyslipidemic agents |
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
-
1998
- 1998-09-08 MA MA25245A patent/MA24643A1/fr unknown
- 1998-09-16 AT AT98951408T patent/ATE294152T1/de not_active IP Right Cessation
- 1998-09-16 EP EP98951408A patent/EP1017659B1/de not_active Expired - Lifetime
- 1998-09-16 JP JP2000511728A patent/JP2001516732A/ja active Pending
- 1998-09-16 WO PCT/EP1998/005874 patent/WO1999014174A1/de not_active Ceased
- 1998-09-16 ES ES98951408T patent/ES2242302T3/es not_active Expired - Lifetime
- 1998-09-16 PT PT98951408T patent/PT1017659E/pt unknown
- 1998-09-16 AU AU97442/98A patent/AU9744298A/en not_active Abandoned
- 1998-09-16 US US09/508,958 patent/US6586613B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001516732A5 (enExample) | ||
| JP2003520235A5 (enExample) | ||
| JP2001516757A5 (enExample) | ||
| JP3316661B2 (ja) | 〔（ヒドロキシフェニルアミノ）カルボニル〕ピロール | |
| JP5278450B2 (ja) | ソリフェナシン又はその塩の製造法 | |
| JP2003532731A5 (enExample) | ||
| HUT67276A (en) | Stereoselective preparation of substituted piperidines | |
| JP2002523395A5 (enExample) | ||
| JP2005533804A5 (enExample) | ||
| JP2002523396A5 (enExample) | ||
| WO1998047505A9 (en) | Neuropeptide y receptor antagonist | |
| RU2002131886A (ru) | Азабициклические карбаматы и их применение в качестве агонистов альфа-7 никотинового ацетилхолинового рецептора | |
| JP2005526836A5 (enExample) | ||
| JP2002518502A5 (enExample) | ||
| JP2007510707A5 (enExample) | ||
| RU2006144710A (ru) | Новые производные циклопента [b] бензофурана и их применение | |
| JP2006525299A (ja) | アゼチジンカルボキサミド誘導体及びｃｂ１レセプター媒介障害の治療におけるその使用 | |
| CA2586689A1 (en) | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | |
| CA2524898A1 (en) | 6-arylmethyl-substituted pyrazolopyrimidines | |
| JP2001524477A5 (enExample) | ||
| RU2323211C2 (ru) | Новые производные бензимидазола, способы их получения, их применение и содержащая их фармацевтическая композиция | |
| RU2000111517A (ru) | Производные трициклического триазолобензазепина, способ их получения и противоаллергические агенты | |
| LU87600A1 (fr) | Composes chimiques | |
| JP2003513075A5 (enExample) | ||
| Moszner et al. | Synthesis of bis (3-{[2-(allyloxy) ethoxy] methyl}-2, 4, 6-trimethylbenzoyl)(phenyl) phosphine oxide–a tailor-made photoinitiator for dental adhesives |